Involved-site radiation therapy

RADIATION2 trials

Sponsors

Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI)

Conditions

Hodgkin LymphomaLugano Classification Limited Stage Hodgkin Lymphoma AJCC v8Relapsed or Refractory Hodgkin Lymphoma

Phase 2

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

RecruitingNCT03618550

Memorial Sloan Kettering Cancer CenterHodgkin Lymphoma, Relapsed or Refractory Hodgkin Lymphoma

Start: 2018-08-01End: 2027-08-01Target: 257Updated: 2026-08-07

Phase 3

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

RecruitingNCT05675410

National Cancer Institute (NCI)Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

Start: 2023-05-11End: 2031-04-28Target: 1875Updated: 2026-09-18

Related Papers

Pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy in relapsed or refractory Hodgkin lymphoma: 5-year update of a multicenter, Phase 2 trial

Blood2025-11-03

AHOD2131: A Randomized Phase 3 Response-Adapted Trial Comparing Standard Therapy with Immuno-Oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

Blood2023-11-0213 citations

Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

Journal of Clinical Oncology2021-06-25182 citations